Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effect of GABAergic Treatments on Cortical Plasticity and Motor Learning Capacity in the Subacute Phase After Stroke (GABAPLAST)

12. November 2026 aktualisiert von: University Hospital, Toulouse

Effect of GABAergic Treatments on Cortical Plasticity and Motor Learning Capacity in the Subacute Phase After Stroke: a Single-case Experimental Study

The GABAPLAST study explores how commonly prescribed GABAergic drugs prescribed during post-stroke rehabilitation affect cortical plasticity and motor learning capacity. Using a multiple-baseline single-case design, the study evaluates the effects of Baclofen, Oxazepam, and Gabapentin in subacute stroke patients according to their clinical indication. Cortical plasticity capacity is measured with transcranial magnetic stimulation and Paired Associative Stimulation (TMS/PAS). The study aims to determine whether these drugs interfere with or preserve brain plasticity during recovery.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Scientific rationale Functional recovery after stroke relies on neuroplasticity, the brain's ability to reorganize neural connections. During the subacute phase, high synaptic plasticity allows efficient motor relearning, but GABAergic inhibition may reduce these mechanisms. Several animal and human studies suggest that increased GABAergic activity limits long-term potentiation of plasticity (LTP-like) and motor learning. Baclofen (GABA-B agonist), Oxazepam (GABA-A agonist), and Gabapentin (GABA modulator) are routinely prescribed to treat spasticity, anxiety, or neuropathic pain after stroke, yet their neurophysiological effects remain unclear. GABAPLAST aims to provide the first controlled experimental evidence of their direct influence on cortical plasticity and implicit motor learning in subacute stroke patients.

Treatment/strategy/procedure and follow up

The study comprises 26 repeated assessment sessions performed five times per week, from Monday to Friday, over approximately six weeks. Each participant will receive one of the following medications according to their clinical indication: oxazepam for anxiety; baclofen for spasticity; gabapentin for neuropathic pain. Each participant will undergo two consecutive phases:

  • Phase A: baseline phase without exposure to the study medication;
  • Phase B: phase with exposure to the study medication, including dose titration and treatment at the clinically appropriate dose.

The duration of Phase A will be randomized to 6, 9 or 12 repeated assessments. Phase B will comprise 20, 17 or 14 assessments, respectively, so that each participant completes a total of 26 assessments.

During Phase A, participants in the oxazepam SCED may receive appropriate non-pharmacological usual-care interventions, such as psychological support, relaxation techniques, sophrology or psychotherapy, according to their clinical needs. If immediate pharmacological treatment becomes necessary, the participant will discontinue the study and receive the appropriate treatment without delay.

Medication doses will be adjusted by the investigator according to usual clinical practice, treatment efficacy and tolerability, within the limits defined in the relevant Summary of Product Characteristics and the dose-titration schedules specified in the protocol. Dose changes, dates and reasons for adjustment will be documented in the electronic case report form.

Each assessment session will include: tablet-based motor learning tasks: the Serial Reaction Time Task and Target Jump Task; TMS/PAS assessment of cortical excitability and plasticity; standardized collection of adverse events.

Studientyp

Interventionell

Einschreibung (Geschätzt)

12

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Toulouse, Frankreich, 31 059
        • Raymonde Fournet Purpan Hospital - Toulouse University Hospital
        • Kontakt:
        • Hauptermittler:
          • Emmeline Montané, MD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults (≥18 years) with ischemic or hemorrhagic stroke in the subacute phase (2 weeks-6 months)
  • Non-urgent clinical indication for oxazepam, baclofen or gabapentin, with the protocol-defined treatment initiation interval considered medically acceptable by the investigator
  • PGI-S score of at least 2 for the symptom leading to treatment prescription
  • Ability to understand and consent (BDAE score >3)
  • Brain MRI available for neuronavigation
  • No motor impairment in the non-paretic hand
  • Affiliation with a national health insurance system
  • Free, informed and written informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any review required by the research).

Exclusion Criteria:

  • Current or recent treatment, within the previous 7 days, with a gabaergic drug of interest (oxazepam, gabapentin, baclofen)

  • Current or recent treatment, within the previous 7 days, with any prohibited treatment (benzodiazepine, Z-drug, morphine, pregabalin, sedative antipsychotic or barbiturate).

  • History of neurological disorders other than stroke, for example: neurodegenerative disease, multiple sclerosis, epilepsy, brain tumour, hydrocephalus.

  • History of severe psychiatric conditions, such as schizophrenia or bipolar disorder

  • Need for immediate initiation of the planned medication

    • Oxazepam: severe respiratory failure, untreated sleep apnoea syndrome, severe acute or chronic hepatic impairment, myasthenia gravis, hypersensitivity to oxazepam or any excipient, galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
    • Baclofen: hypersensitivity to baclofen or any excipient, wheat allergy, or coeliac disease
    • Gabapentin: hypersensitivity to gabapentin or any excipient, galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
  • Presence of a psychoactive substance dependence

  • Pregnancy or breast-feeding

  • Skin disorder in the stimulated hand indicating the placement of electromyographic collection or stimulation electrodes

  • Medical contraindications for the performance of MSDs according to the TMS safety questionnaire

  • Presence of a major peripheral neuromuscular disorder (e.g. severe motor neuropathy) making the interpretation of PEM unreliable.

  • Guardianship, curatorship, safeguarding of justice

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Baclofen SCED

The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, baclofen intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction.

Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:

  • Phase A: baseline phase without exposure to the study medication, comprising 6, 9 or 12 repeated assessments according to randomized allocation.
  • Phase B: phase with exposure to baclofen, including dose titration and treatment at the clinically appropriate dose. Phase B comprises 20, 17 or 14 repeated assessments, respectively, so that each participant completes a total of 26 assessments.
Experimental: Oxazepam SCED

The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, oxazepam intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction.

Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:

  • Phase A: baseline phase without exposure to the study medication, comprising 6, 9 or 12 repeated assessments according to randomized allocation.
  • Phase B: phase with exposure to oxazepam, including dose titration and treatment at the clinically appropriate dose. Phase B comprises 20, 17 or 14 repeated assessments, respectively, so that each participant completes a total of 26 assessments
Experimental: Gabapentin SCED

The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, gabapentin intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction.

Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:

  • Phase A: baseline phase without exposure to the study medication, comprising 6, 9 or 12 repeated assessments according to randomized allocation.
  • Phase B: phase with exposure to gabapentin, including dose titration and treatment at the clinically appropriate dose. Phase B comprises 20, 17 or 14 repeated assessments, respectively, so that each participant completes a total of 26 assessments

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Brain plasticity
Zeitfenster: 6 weeks

It will be assessed by the change in the amplitude of the motor evoked potential (MEP) induced by a Paired Associative Stimulation (PAS) protocol, expressed as the percentage change between the pre-PAS and post-PAS measurements. The variation represents the degree of brain plasticity induced by the PAS protocol during a session. It will be done during all the assessments of phase A and phase B.

6 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Cortical excitability: Membrane excitability of neurons in the motor cortex
Zeitfenster: 6 weeks

It will be assessed by the Resting Motor Threshold (RMT), defined as the minimum stimulation intensity, expressed as a percentage of the Maximum Stimulator Output (MSO), that elicits at least 5 motor evoked potentials (PEM) ≥ 50 µV in 10 trials. It will be done during each session of phase A and phase B (except on the last day of each phase).

6 weeks
Cortical excitability: Changes in cortical membrane excitability induced by the PAS protocol
Zeitfenster: 6 weeks

It will be assessed by the change (Δ) in RMT induced by the PAS protocol, expressed as the percentage change between the RMT measured immediately after PAS and the RMT measured before PAS. It will be done during each session of phase A and phase B (except on the last day of each phase).

6 weeks
Cortical excitability: Overall response of the corticospinal tract
Zeitfenster: 6 weeks

It will be assessed by the PEM amplitude at the RMT, defined as the "peak-to-peak" average (µV) calculated from a series of 20 PEMs recorded at the RMT. It will be done during each session of phase A and phase B (except on the last day of each phase).

6 weeks
Cortical excitability: Conduction and functional integrity of corticospinal tracts
Zeitfenster: 6 weeks

It will be assessed by the PEM latency at the RMT, defined as the time (ms) between the magnetic pulse and the onset of the muscle response, averaged over 20 trials. It will be done during each session of phase A and phase B (except on the last day of each phase).

6 weeks
Motor learning performance: general learning effect assessed by SRTT
Zeitfenster: 6 weeks

The general learning effect will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the decrease in normalized reaction time (%mRT) between block 2 and block 4 (sequence).

During the SRTT, the participant must slide their finger from one position to another as quickly as possible, in response to a visual stimulus appearing at one of the four locations on the screen. In the sequenced condition, a sequence of 8 movements is repeated six times per block, while in the random condition, the 48 positions appear in a random order. The blocks follow the same alternation (R-S-S-S-R-S), allowing for the isolation of effects related to the learning of motor sequences.

6 weeks
Motor learning performance: specific learning effect assessed by SRTT
Zeitfenster: 6 weeks

The specific learning effect will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the increase in %mRT in block 5 (random) compared to block 4 (sequence).

6 weeks
Motor learning performance: retention assessed by SRTT
Zeitfenster: 6 weeks

The retention will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the change in %mRT between block 6 (sequence) and block 5 (random).

6 weeks
Motor learning performance: general learning effect assessed by Target Jump tasks
Zeitfenster: 6 weeks

The general learning effect will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the decrease in normalized reaction time (%mRT) between block 2 and block 4 (sequence).

During the Target Jumps tasks, the participant must return their finger to the lower center of the screen before each trial, then slide it toward the target that appears. The target shifts a few centimeters as the participant begins the movement. The blocks alternate according to the pattern R-S-S-S-R-S, with random or systematic shifts, allowing for the exploration of visuomotor adaptation abilities.

6 weeks
Motor learning performance: specific learning effect assessed by Target Jump tasks
Zeitfenster: 6 weeks

The specific learning effect will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the increase in %mRT in block 5 (random) compared to block 4 (sequence).

6 weeks
Motor learning performance: retention assessed by Target Jump tasks
Zeitfenster: 6 weeks

The retention will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the change in %mRT between block 6 (sequence) and block 5 (random).

6 weeks
Severity of the symptom that lead to initial treatment prescription
Zeitfenster: 6 weeks

It will be reported by the patient using the Patient Global Impression of Severity PGI-S completed at inclusion, on the last day of phase A and last day of phase B.

This scale ranges from 1 ("no discomfort/pain/anxiety") to 4 ("severe"). Each patient will complete only one PGI-S form, corresponding to the symptom being treated by the study drug.

6 weeks
Safety of participants
Zeitfenster: 6 weeks

It will be assessed by the spontaneous report on adverse events, assessed at each session.

6 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Emmeline Montané, MD, University Hospital, Toulouse

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. November 2026

Primärer Abschluss (Geschätzt)

1. Mai 2028

Studienabschluss (Geschätzt)

1. Mai 2028

Studienanmeldedaten

Zuerst eingereicht

5. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2026

Zuerst gepostet (Tatsächlich)

17. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • RC31/25/0619
  • 2026-526884-39-00 (Andere Kennung: EU-CT)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .